Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary ...

Cat Oyler, Global Head of External Innovation Strategy and Operations at Johnson & Johnson (J&J), has an ambitious and compelling vision for the future of healthcare: a world without disease.

Johnson & Johnson has a strong business, several growth opportunities, and a safe dividend. The company does face headwinds, but it should be able to overcome them. Some might describe Johnson ...

Johnson & Johnson’s Consumer Health segment reported a revenue of $14.6 billion in the Full-Year 2021. It is projected that, following the separation, Kenvue will generate sales in over 100 ...

Johnson & Johnson is acquiring biopharmaceutical company Intra-Cellular Therapies for $14.6 billion. It has an approved depression and schizophrenia treatment that could generate $5 billion in ...

Johnson & Johnson (JNJ) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Julie Whytock, 64, from Hertfordshire, says she developed ovarian cancer after using Johnson & Johnson (J&J) talc powder ‘at least once a day’ as a young child. After her diagnosis with stage ...

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy. However ...

Healthcare conglomerate Johnson & Johnson on Tuesday kicked off a bankruptcy-court trial on its third attempt to resolve one of the largest-ever mass tort lawsuits through a chapter 11 case.